# Moyamoya Disease Market

> Moyamoya Disease Market Research Report Information: By Diagnosis (Cerebral Angiogram, Mri, Mra, Ct Scan, Transcranial Doppler Ultrasound, Pet Scan, Electroencephalography), Treatment (Surgical, Non-Surgical Treatment), Distribution Channel -Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.04%
- **2024:** $ 1.27 Billion
- **2025:** $ 1.32 Billion
- **2035:** $ 1.96 Billion
- **Key Players:** Bristol-Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer(US), AstraZeneca (GB), Sanofi (FR), Eli Lilly and Company (US), Teva Pharmaceutical Industries (IL), Amgen (US)

**Report ID:** MRFR/MED/3837-HCR · **Pages:** 85 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/moyamoya-disease-market-5275

---

## Market Summary

## **Moyamoya Disease Market Overview**

Moyamoya Disease Market Size was valued at USD 1.22 Billion in 2023. The Global Moyamoya Disease industry is projected to grow from USD 1.36 Billion in 2024 to USD 1.76 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.10%during the forecast period (2024 - 2032).

Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.

According to the National Organization for Rare Diseases, in Japan, moyamoya disease is estimated to occur in 1 per 1 million people, and the condition is more prevalent in females under the age of 20. It is also reported that nearly 10% of cases of moyamoya disease in Asian countries have a genetic cause. Recently, two major mutations have been found to be associated with a specific population of moyamoya patients i.e. R179, and RNF213 mutations.

**Intended Audience**

## **Moyamoya Disease Market Key Players**

Some of key the players in the moyamoya disease market are: 

**Research Methodology**

Sources: Annual reports, Press release, White paper, and Company presentation

It is noted that growing public awareness and technological advancements are the key factors driving the moyamoya disease market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and health conscious. Thus, increasing awareness has provided a push to the growth of the market. The new and existing marketers are also contributing to control this condition.

For instance, on April 13, 2016, Silk Road Medical, Inc., received FDA approval for its next-generation ENROUTE Transcarotid Neuroprotection System (NPS). The NPS is specifically designed and indicated for transcarotid artery revascularization.

Various other factors such as increased incidence of neurological disorders, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the moyamoya disease market.

Despite these drivers, there are some issues associated with moyamoya disease market. The challenges in research and development, cost of treatment, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.

## **Moyamoya Disease Market Segmentation**

The moyamoya disease market is segmented on the basis of diagnosis, treatment, and distribution channels.

On the basis of the diagnosis, the market is classified as a cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance angiogram (MRA), computed tomography (CT) scans, transcranial [Doppler ultrasound](../../../reports/doppler-ultrasound-market-8361), positron emission tomography (PET) scan, and electroencephalography (EEG).

On the basis of the treatment, the moyamoya disease market is classified as surgical treatment and non-surgical treatment. The surgical treatment is further classified as pial synangiosis, indirect procedures, and direct arterial bypass. The sub-segment of indirect procedures includes EDAS (encephaloduroarteriosynangiosis), EMS (encephalomyosynangiosis), Omental transposition/transfer, and dural inversion. The non-surgical treatment is further classified as anticoagulation and antiplatelet therapy, and others. The sub-segment of anticoagulation and antiplatelet therapy include heparin, warfarin, aspirin, and others.

On the basis of the distribution channel, the moyamoya disease market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies and others.

## **Moyamoya Disease Market Regional Analysis**

The Americas dominate the moyamoya disease market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the moyamoya disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive European market.

The Asia Pacific is the fastest growing moyamoya disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015

The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.

## Market Drivers

### Enhanced Diagnostic Technologies

The Moyamoya Disease Market is benefiting from enhanced diagnostic technologies that facilitate earlier and more accurate detection of the disease. Advanced imaging techniques, such as magnetic resonance angiography (MRA) and computed tomography angiography (CTA), are becoming increasingly accessible and are crucial for timely diagnosis. The ability to identify Moyamoya disease at an earlier stage can lead to prompt intervention, which is essential for improving patient outcomes. As diagnostic capabilities improve, the number of diagnosed cases is likely to rise, thereby increasing the demand for treatment options within the Moyamoya Disease Market. This trend may also encourage healthcare providers to invest in state-of-the-art diagnostic equipment.

### Advancements in Surgical Techniques

The Moyamoya Disease Market is witnessing significant advancements in surgical techniques, which are crucial for effective treatment. Procedures such as direct and indirect revascularization have evolved, leading to improved patient outcomes. These innovations not only enhance the safety and efficacy of surgeries but also reduce recovery times, making them more appealing to patients and healthcare providers alike. As surgical options become more refined, the demand for these procedures is likely to increase, thereby propelling the Moyamoya Disease Market forward. Furthermore, the integration of minimally invasive techniques may attract a broader patient base, contributing to market growth.

### Increasing Incidence of Moyamoya Disease

The Moyamoya Disease Market is experiencing a notable increase in the incidence of this rare cerebrovascular disorder. Recent epidemiological studies indicate that the prevalence of Moyamoya disease is rising, particularly among certain demographics, such as individuals of Asian descent. This increase in cases is likely to drive demand for diagnostic and therapeutic options, thereby expanding the market. As healthcare providers become more aware of the disease, the number of diagnosed cases is expected to grow, leading to a greater need for specialized treatment facilities and resources. Consequently, this trend may stimulate investment in research and development, ultimately enhancing the Moyamoya Disease Market.

### Growing Investment in Research and Development

Investment in research and development within the Moyamoya Disease Market is on the rise, driven by the need for better understanding and treatment of this complex condition. Pharmaceutical companies and research institutions are increasingly allocating resources to explore novel therapeutic agents and innovative treatment modalities. This influx of funding is expected to yield breakthroughs in drug development and clinical trials, potentially leading to more effective therapies for patients. As the scientific community continues to unravel the underlying mechanisms of Moyamoya disease, the market may see a surge in new products and treatment options, enhancing the overall landscape of the Moyamoya Disease Market.

### Rising Awareness Among Healthcare Professionals

Rising awareness among healthcare professionals regarding Moyamoya disease is a pivotal driver for the Moyamoya Disease Market. As more clinicians become educated about the symptoms and implications of this rare condition, the likelihood of early diagnosis and appropriate treatment increases. Educational initiatives and training programs are being implemented to equip healthcare providers with the knowledge necessary to recognize and manage Moyamoya disease effectively. This heightened awareness is expected to lead to an increase in referrals to specialized centers, thereby boosting the demand for both diagnostic and therapeutic services. Consequently, this trend is likely to have a positive impact on the Moyamoya Disease Market.

## Future Outlook

The Moyamoya Disease Market is projected to grow at a 4.04% CAGR from 2025 to 2035, driven by advancements in surgical techniques, increased awareness, and improved diagnostic tools.

**New opportunities:**

- Development of targeted therapies for Moyamoya Disease Market patients Expansion of telemedicine services for remote patient monitoring Investment in clinical trials for innovative treatment options

By 2035, the Moyamoya Disease Market is expected to achieve substantial growth and enhanced treatment accessibility.

## Segment Insights

### By Diagnosis: Magnetic Resonance Angiogram (Largest) vs. Cerebral Angiogram (Fastest-Growing)

In the Moyamoya Disease Market, the diagnosis segment showcases a diverse array of imaging technologies, each contributing uniquely to the identification and understanding of the disease. Notably, the Magnetic Resonance Angiogram (MRA) holds the largest share, owing to its non-invasive nature and high-resolution imaging capabilities that distinctly visualize cerebral blood vessels. Following closely is the Cerebral Angiogram, which, while invasive, provides definitive diagnosis capability, making it highly valued in clinical settings despite a smaller share compared to MRA. The growth trends within the diagnosis segment of Moyamoya Disease Market are fueled by advancements in imaging technology and increased awareness of the disease. This awareness leads to enhanced screening and better diagnostic rates across populations. Innovations in imaging modalities, particularly in Non-Invasive techniques like MRI and MRA, are projected to witness significant adoption, while the Cerebral Angiogram is expected to garner attention for complex cases, further aiding its growth in the market.

Magnetic Resonance Angiogram (Dominant) vs. Cerebral Angiogram (Emerging)

The Magnetic Resonance Angiogram (MRA) is currently the dominant imaging modality within the diagnosis segment of Moyamoya [Disease](https://www.marketresearchfuture.com/reports/olliers-disease-market-38943)due to its ability to produce clear and detailed images of blood vessels without the need for invasive procedures. It enables clinicians to visualize the extent and severity of vascular occlusions or other abnormalities. In contrast, the Cerebral Angiogram is recognized as an emerging technology, renowned for its precision in diagnosis but limited by its invasive nature. This segment is now seeing improvements with the advent of newer techniques that may mitigate associated risks, aligning it closer to current diagnostic standards while establishing its significance in accurately diagnosing complicated cases of Moyamoya.

### By Treatment: Surgical Treatment (Largest) vs. Non-Surgical Treatment (Fastest-Growing)

In the Moyamoya Disease Market, the surgical treatment segment holds the largest share, accounting for a significant proportion of the overall treatment strategies employed by healthcare providers. Surgical interventions, such as bypass surgery, are often preferred due to their effectiveness in improving cerebral blood flow and preventing further ischemic events. On the other hand, the non-surgical treatment segment, which includes medical management and lifestyle modifications, is experiencing rapid growth as awareness about the disease increases and patient-centered approaches gain traction. This has contributed to a diversification of treatment options available for patients.

Treatment Approaches: Surgical (Dominant) vs. Non-Surgical (Emerging)

The surgical treatment approach for Moyamoya Disease Market is characterized by established procedures that have demonstrated substantial operational success in alleviating symptoms and improving patient outcomes. It is regarded as the dominant method due to its proven efficacy in restoring blood flow to the brain through surgical revascularization techniques. Meanwhile, the non-surgical treatment approach, while emerging, is gaining recognition as a complement to surgical options. This encompasses pharmacological management and non-invasive interventions aimed at optimizing patient quality of life. As medical technologies advance and new drugs are developed, non-surgical methods are expected to see increasing application, appealing to a broader patient demographic looking for alternatives or adjuncts to surgical procedures.

### By Distribution Channel: Hospitals (Largest) vs. Pharmacies (Fastest-Growing)

In the Moyamoya Disease Market, hospitals represent the largest distribution channel, accommodating high patient volumes and offering specialized treatment options. Their critical role in patient diagnosis and intervention significantly contributes to their dominating market share, as they are equipped with advanced technologies and a multidisciplinary approach to patient care. Conversely, while hospitals lead in size, pharmacies are emerging as a fast-growing distribution avenue, reflecting a shift toward more accessible patient services and support in managing Moyamoya Disease Market treatment regimens.

Hospitals (Dominant) vs. Pharmacies (Emerging)

Hospitals play a dominant role in the Moyamoya Disease Market due to their comprehensive capabilities in providing complex care, surgeries, and ongoing management. They are often the first point of contact for patients experiencing symptoms, equipped with neurologists and neurosurgeons specialized in this condition. In contrast, pharmacies are emerging as vital partners in managing treatment adherence, offering specialized medications and educating patients about their therapies. The growth of pharmacies is driven by an increasing demand for convenient access to medications and patient education services, reflecting a trend toward decentralizing care and empowering patients to manage their health more effectively.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for Moyamoya disease treatment, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a growing awareness of rare diseases. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving market growth. The increasing prevalence of Moyamoya disease, particularly among pediatric populations, further fuels demand for effective treatment options.

The United States is the primary contributor to this market, with key players such as Bristol-Myers Squibb, Pfizer, and Eli Lilly leading the charge in developing new therapies. Canada also plays a significant role, focusing on research and collaboration with U.S. institutions. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms, all striving to address unmet medical needs in Moyamoya disease treatment.

### Europe : Emerging Market with Potential

Europe is the second-largest market for Moyamoya disease, holding approximately 30% of the global market share. The region is witnessing a surge in interest towards rare diseases, driven by increasing healthcare expenditure and supportive regulatory frameworks. The European Medicines Agency (EMA) has been proactive in facilitating the approval of orphan drugs, which is crucial for the treatment of Moyamoya disease. This regulatory environment is expected to enhance market growth in the coming years.

Leading countries in this region include Germany, France, and the United Kingdom, where healthcare systems are increasingly focusing on rare disease management. Key players like Novartis and Roche are actively involved in research and development, aiming to introduce innovative therapies. The competitive landscape is evolving, with collaborations between pharmaceutical companies and research institutions to enhance treatment options for Moyamoya disease.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is an emerging market for Moyamoya disease, accounting for approximately 20% of the global market share. The region is experiencing rapid growth due to increasing healthcare investments, rising awareness of rare diseases, and improving access to advanced medical technologies. Countries like Japan and China are leading this growth, with significant government initiatives aimed at enhancing healthcare infrastructure and promoting research in rare diseases.

Japan is particularly notable for its advanced healthcare system and strong focus on rare disease research. Key players such as Teva Pharmaceutical Industries and Amgen are expanding their presence in this region, driven by the growing demand for effective treatments. The competitive landscape is characterized by a mix of local and international companies, all vying to capture market share in this promising sector.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa represent a nascent market for Moyamoya disease, holding approximately 5% of the global market share. The region faces challenges such as limited healthcare infrastructure and a lack of awareness regarding rare diseases. However, there is a growing recognition of the need for specialized treatments, which presents opportunities for market growth. Governments are increasingly investing in healthcare improvements, which could catalyze market development in the coming years.

Countries like South Africa and the UAE are beginning to focus on rare disease management, with initiatives aimed at improving patient access to treatments. The competitive landscape is still developing, with few key players currently active in the region. However, as awareness grows, there is potential for both local and international companies to enter the market and address the unmet needs of patients suffering from Moyamoya disease.

## Competitive Benchmarking

The Moyamoya Disease Market is characterized by a complex interplay of competitive dynamics, driven by a growing awareness of the disease and advancements in treatment options. Key players such as Bristol-Myers Squibb (US), Novartis (CH), and Roche (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Bristol-Myers Squibb (US) focuses on innovation through research and development, particularly in the realm of targeted therapies, while Novartis (CH) emphasizes strategic partnerships to bolster its pipeline. Roche (CH), on the other hand, is leveraging its extensive experience in neurology to develop comprehensive treatment solutions, thereby shaping a competitive environment that is increasingly reliant on innovation and collaboration.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Moyamoya Disease Market appears moderately fragmented, with a mix of established players and emerging biotech firms. This structure allows for a diverse range of treatment options, although the influence of key players remains substantial, as they set benchmarks for quality and efficacy in treatment protocols.

In August 2025, Novartis (CH) announced a collaboration with a leading research institution to explore gene therapy approaches for Moyamoya Disease. This strategic move is significant as it not only enhances Novartis's research capabilities but also positions the company as a pioneer in innovative treatment modalities, potentially leading to breakthroughs that could redefine patient outcomes.

In September 2025, Roche (CH) launched a new clinical trial aimed at evaluating the long-term efficacy of its latest drug candidate for Moyamoya Disease. This initiative underscores Roche's commitment to advancing treatment options and reflects a broader trend in the industry towards rigorous clinical validation, which is essential for gaining regulatory approval and ensuring patient safety.

In October 2025, Bristol-Myers Squibb (US) expanded its global footprint by entering into a strategic alliance with a prominent healthcare provider in Asia. This partnership is likely to enhance access to innovative therapies in emerging markets, thereby aligning with the company's goal of increasing patient access to cutting-edge treatments and reinforcing its competitive position in the global market.

As of October 2025, the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource pooling among companies. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Report Scope

| MARKET SIZE 2024 | 1.269(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.321(USD Billion) |
| MARKET SIZE 2035 | 1.962(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.04% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer (US), AstraZeneca (GB), Sanofi (FR), Eli Lilly and Company (US), Teva Pharmaceutical Industries (IL), Amgen (US) |
| Segments Covered | Diagnosis |
| Key Market Opportunities | Advancements in surgical techniques and therapies enhance treatment options in the Moyamoya Disease Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and investment in Moyamoya Disease treatment advancements. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Moyamoya Disease Market in 2035?**
A: The projected market valuation for the Moyamoya Disease Market in 2035 is 1.962 USD Billion.

**Q: What was the overall market valuation for the Moyamoya Disease Market in 2024?**
A: The overall market valuation for the Moyamoya Disease Market in 2024 was 1.269 USD Billion.

**Q: What is the expected CAGR for the Moyamoya Disease Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Moyamoya Disease Market during the forecast period 2025 - 2035 is 4.04%.

**Q: Which companies are considered key players in the Moyamoya Disease Market?**
A: Key players in the Moyamoya Disease Market include Bristol-Myers Squibb, Novartis, Roche, Pfizer, AstraZeneca, Sanofi, Eli Lilly and Company, Teva Pharmaceutical Industries, and Amgen.

**Q: What are the main segments of the Moyamoya Disease Market?**
A: The main segments of the Moyamoya Disease Market include Diagnosis, Treatment, and Distribution Channel.

**Q: What was the valuation of Surgical Treatment in the Moyamoya Disease Market in 2024?**
A: The valuation of Surgical Treatment in the Moyamoya Disease Market in 2024 was between 0.635 and 0.951 USD Billion.

**Q: How much is the Non-Surgical Treatment segment projected to be worth in 2035?**
A: The Non-Surgical Treatment segment is projected to be worth between 0.634 and 1.011 USD Billion in 2035.

**Q: What is the valuation range for Magnetic Resonance Imaging (MRI) in the Moyamoya Disease Market?**
A: The valuation range for Magnetic Resonance Imaging (MRI) in the Moyamoya Disease Market is between 0.3 and 0.45 USD Billion.

**Q: Which distribution channel had the highest valuation in 2024?**
A: In 2024, the Hospitals distribution channel had the highest valuation, ranging from 0.38 to 0.57 USD Billion.

**Q: What is the projected valuation for the Positron Emission Tomography (PET) Scan segment in 2035?**
A: The projected valuation for the Positron Emission Tomography (PET) Scan segment in 2035 is between 0.05 and 0.075 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/moyamoya-disease-market-5275*